In a recent paper, Pimentel et al., using mice with a single tumor, found a better effect for triple treatment with RT, tumor neovasculature-targeting L19-IL-2, and anti-PD1 compared to RT/anti-PD1 or RT/L19-IL-2 in the LLC model; in the CT26 and C51 colon carcinoma models the differences were significant only compared to RT/anti-PD129. The gene discussed is IL2; the disease is colon carcinoma.